COMMUNIQUÉS West-GlobeNewswire

BrainsWay Reports Expansion of Adolescent Depression Coverage Applicable to Deep TMS™
22/12/2025
Optum Behavioral Health, a Health Services Company with Over 48 Million Covered Lives, Joins Growing List of Insurers Now Covering Deep TMS Depression Therapy for Adolescents Aged 15 and Older BURLINGTON, Mass. and [...]
XOMA Royalty Declares Quarterly Preferred Stock Dividends
22/12/2025
EMERYVILLE, Calif., Dec. 22, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (Nasdaq: XOMA), the biotech royalty aggregator, today announced its Board of Directors has authorized the following cash dividends to [...]
Lexeo Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
22/12/2025
NEW YORK, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc . (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced that [...]
Rectify and Boehringer Ingelheim Collaborate to Advance First-in-class Treatments for Chronic Kidney Disease
22/12/2025
Collaboration aims to accelerate the development of treatments for chronic kidney disease (CKD) and other conditions Rectify has developed oral, small molecules that can potentially reduce calcification by enhancing the [...]
Oncotelic Therapeutics Details PDAOAI Platform and Opens Access to Its Total TGF-β Knowledge Corpus
22/12/2025
AGOURA HILLS, Calif., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or “Our”), a leader in RNA-based therapeutics, announced today opened access to [...]
Nasus Pharma CEO Issues 2025 Letter to Shareholders
22/12/2025
TEL AVIV, Israel, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma", “Nasus” or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal [...]
Sinaptica Therapeutics Completes Scientific Advisory Board, Bringing Together Leading Voices Across Patients, Science, Medicine, and Commercial Strategy
22/12/2025
CAMBRIDGE, Mass., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Sinaptica Therapeutics, a clinical-stage company leading the development of a new class of personalized neuromodulation therapeutics to treat Alzheimer’s and other [...]
SCYNEXIS Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement
22/12/2025
JERSEY CITY, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today [...]
ORYZON Expands Global Patent Protection for Iadademstat with Grant Decision in Japan Covering Combinations with PD-1/PD-L1 Inhibitors
22/12/2025
Key combination for the treatment of Small Cell Lung Cancer MADRID and CAMBRIDGE, Mass., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company [...]
Immutep Announces Positive Update on IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases, from Phase I Study
22/12/2025
Single-ascending dose portion of study has successfully completed 2.5 and 7 mg / kg levels Dose dependent immunosuppressive effect against a strong foreign antigen observed with continued favourable safety profile [...]
Humacyte Announces Publication of Long-Term Safety and Efficacy Results of Symvess® in Extremity Trauma Repair
22/12/2025
- Results published in Journal of Vascular Surgery Cases, Innovations and Techniques (JVS-CIT) - - After up to 36 months of follow-up, patients demonstrated high limb salvage, low rates of infection, no unprovoked [...]
ArriVent Announces First Patient Dosed in Global Pivotal Phase 3 ALPACCA Trial Evaluating Firmonertinib for First-Line Treatment of EGFR PACC Mutant Non-Small Cell Lung Cancer
22/12/2025
Firmonertinib has the potential to redefine first-line treatment in this underserved population as a once daily, oral, brain-penetrant, chemo-free monotherapy ALPACCA pivotal trial is designed to support potential [...]
RESTEM to Present Company Overview in Biotech Showcase 2026
22/12/2025
MIAMI, Dec. 22, 2025 (GLOBE NEWSWIRE) -- RESTEM – a clinical-stage biotechnology company that develops off-the-shelf, next-generation cell therapies designed to modulate the immune system, today announced its [...]
CoRegen Appoints Globally Recognized Surgeon-Scientist Bert O’Malley Jr. to its Board of Directors
22/12/2025
HOUSTON, Dec. 22, 2025 (GLOBE NEWSWIRE) -- CoRegen, Inc. , a biopharmaceutical company pursuing novel treatments for patients impacted by some of the most aggressive forms of solid tumor cancer, today announced the [...]
SCIENTURE Provides Update on the Commercial Launch of REZENOPY®, the Highest Strength Naloxone HCl Life-Saving Opioid Overdose Emergency Treatment Approved by the FDA
22/12/2025
U.S. Naloxone Market: ~$154 million in annual sales and 9.3 million units annually COMMACK, NY, Dec. 22, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned [...]
Vivos Inc Summarzes Preogress in its Animal Therapy Division
22/12/2025
Kennewick, WA, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) The IsoPet division reported an 800% year-over-year increase in administered therapies from 2024 to 2025, reflecting accelerating veterinary [...]
Imviva Biotech Announces First Patient Dosed in Phase 1b/2 TENACITY-01 Trial of CTD402 CAR-T Cell Therapy
22/12/2025
Patient achieved complete remission and well-tolerated safety profile, advancing path to Phase 2 BOSTON, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Imviva Biotech, a clinical-stage biotechnology company developing next- [...]
CRISPR Therapeutics Provides Broad Update on Zugocaptagene Geleucel (Zugo-cel; formerly CTX112™) in Autoimmune Diseases and Hematologic Malignancies
22/12/2025
-Four autoimmune patients treated to date demonstrate deep B-cell depletion sustained for at least 28 days; initial efficacy data suggest significant clinical improvement in patients dosed at the 100 million cell dose, [...]
CVRx to Present at the 44th Annual J.P. Morgan Healthcare Conference
22/12/2025
MINNEAPOLIS, Dec. 22, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions [...]

Pages